Yasuyuki Okada1, Satoshi Nishiwada2, Kensuke Yamamura3, Masayuki Sho4, Hideo Baba3, Tetsuji Takayama5, Ajay Goel6. 1. Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA, USA; Department of Gastroenterology and Oncology, Tokushima University Graduate School, Tokushima, Japan. 2. Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA, USA; Department of Surgery, Nara Medical University, Nara, Japan. 3. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. 4. Department of Surgery, Nara Medical University, Nara, Japan. 5. Department of Gastroenterology and Oncology, Tokushima University Graduate School, Tokushima, Japan. 6. Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: ajgoel@coh.org.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. While the extracellular matrix component plays an integral role in PDAC pathogenesis and mediating chemoresistance, its role in predicting response to chemotherapy in patients with PDAC remains unclear. METHODS: We performed a systematic biomarker discovery by analysing genome-wide transcriptomic profiling data from 423 patients (GSE71729, GSE21501 and The Cancer Genome Atlas [TCGA]) for predicting overall survival (OS). This was subsequently validated in two independent clinical cohorts of 270 patients with PDAC (training cohort, n = 121, and validation cohort, n = 149). In addition, we investigated endoscopic ultrasound-fine needle aspiration biopsy specimens from 51 patients with PDAC with an unresectable cancer for predicting therapeutic response to gemcitabine-based therapy. RESULTS: After rigorous bioinformatic analysis, we identified laminin γ2 (LAMC2) to be a significant prognostic factor in all three PDAC data sets (GSE71729: hazard ratio [HR] = 2.04, P = 0.002; GSE21501: HR = 2.17, P = 0.031; TCGA: HR = 2.57, P < 0.001). High LAMC2 expression in patients with PDAC was associated with a significantly poor OS and relapse-free survival in both the training (P < 0.001, P < 0.001) and validation cohorts (P = 0.001, P = 0.026). More importantly, LAMC2 expression robustly identified patients with PDAC and unresectable disease and those who responded to gemcitabine-based therapy (area under the curve = 0.79; 95% confidence interval [CI], 0.65-0.89). The univariate logistic regression analysis revealed that high LAMC2 expression was the only factor that predicted poor response to gemcitabine in patients with PDAC (odds ratio = 4.90; 95% CI, 1.45-16.6; P = 0.011). CONCLUSION: We conclude that LAMC2 is a novel prognostic and predictive biomarker for gemcitabine-based therapy in both the adjuvant and palliative setting; which could have significant impact on precision and individualised treatment of patients with PDAC.
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. While the extracellular matrix component plays an integral role in PDAC pathogenesis and mediating chemoresistance, its role in predicting response to chemotherapy in patients with PDAC remains unclear. METHODS: We performed a systematic biomarker discovery by analysing genome-wide transcriptomic profiling data from 423 patients (GSE71729, GSE21501 and The Cancer Genome Atlas [TCGA]) for predicting overall survival (OS). This was subsequently validated in two independent clinical cohorts of 270 patients with PDAC (training cohort, n = 121, and validation cohort, n = 149). In addition, we investigated endoscopic ultrasound-fine needle aspiration biopsy specimens from 51 patients with PDAC with an unresectable cancer for predicting therapeutic response to gemcitabine-based therapy. RESULTS: After rigorous bioinformatic analysis, we identified laminin γ2 (LAMC2) to be a significant prognostic factor in all three PDAC data sets (GSE71729: hazard ratio [HR] = 2.04, P = 0.002; GSE21501: HR = 2.17, P = 0.031; TCGA: HR = 2.57, P < 0.001). High LAMC2 expression in patients with PDAC was associated with a significantly poor OS and relapse-free survival in both the training (P < 0.001, P < 0.001) and validation cohorts (P = 0.001, P = 0.026). More importantly, LAMC2 expression robustly identified patients with PDAC and unresectable disease and those who responded to gemcitabine-based therapy (area under the curve = 0.79; 95% confidence interval [CI], 0.65-0.89). The univariate logistic regression analysis revealed that high LAMC2 expression was the only factor that predicted poor response to gemcitabine in patients with PDAC (odds ratio = 4.90; 95% CI, 1.45-16.6; P = 0.011). CONCLUSION: We conclude that LAMC2 is a novel prognostic and predictive biomarker for gemcitabine-based therapy in both the adjuvant and palliative setting; which could have significant impact on precision and individualised treatment of patients with PDAC.
Authors: Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian Journal: Cancer Res Date: 2014-06-01 Impact factor: 12.701
Authors: Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani Journal: Cancer Cell Date: 2012-03-20 Impact factor: 31.743
Authors: Vincent P Groot; Neda Rezaee; Wenchuan Wu; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Lei Zheng; Christopher L Wolfgang; Jin He Journal: Ann Surg Date: 2018-05 Impact factor: 12.969
Authors: Hari Kosanam; Ioannis Prassas; Caitlin C Chrystoja; Ireena Soleas; Alison Chan; Apostolos Dimitromanolakis; Ivan M Blasutig; Felix Rückert; Robert Gruetzmann; Christian Pilarsky; Masato Maekawa; Randall Brand; Eleftherios P Diamandis Journal: Mol Cell Proteomics Date: 2013-06-24 Impact factor: 5.911
Authors: Manuel Hidalgo; Carlos Plaza; Monica Musteanu; Peter Illei; Carrie B Brachmann; Carla Heise; Daniel Pierce; Pedro P Lopez-Casas; Camino Menendez; Josep Tabernero; Alfredo Romano; Xinyu Wei; Fernando Lopez-Rios; Daniel D Von Hoff Journal: Clin Cancer Res Date: 2015-07-13 Impact factor: 12.531
Authors: John P Neoptolemos; Jörg Kleeff; Patrick Michl; Eithne Costello; William Greenhalf; Daniel H Palmer Journal: Nat Rev Gastroenterol Hepatol Date: 2018-06 Impact factor: 46.802
Authors: Pascal Belleau; Dannielle D Engle; Hervé Tiriac; Dennis Plenker; Astrid Deschênes; Tim D D Somerville; Fieke E M Froeling; Richard A Burkhart; Robert E Denroche; Gun-Ho Jang; Koji Miyabayashi; C Megan Young; Hardik Patel; Michelle Ma; Joseph F LaComb; Randze Lerie D Palmaira; Ammar A Javed; Jasmine C Huynh; Molly Johnson; Kanika Arora; Nicolas Robine; Minita Shah; Rashesh Sanghvi; Austin B Goetz; Cinthya Y Lowder; Laura Martello; Else Driehuis; Nicolas LeComte; Gokce Askan; Christine A Iacobuzio-Donahue; Hans Clevers; Laura D Wood; Ralph H Hruban; Elizabeth Thompson; Andrew J Aguirre; Brian M Wolpin; Aaron Sasson; Joseph Kim; Maoxin Wu; Juan Carlos Bucobo; Peter Allen; Divyesh V Sejpal; William Nealon; James D Sullivan; Jordan M Winter; Phyllis A Gimotty; Jean L Grem; Dominick J DiMaio; Jonathan M Buscaglia; Paul M Grandgenett; Jonathan R Brody; Michael A Hollingsworth; Grainne M O'Kane; Faiyaz Notta; Edward Kim; James M Crawford; Craig Devoe; Allyson Ocean; Christopher L Wolfgang; Kenneth H Yu; Ellen Li; Christopher R Vakoc; Benjamin Hubert; Sandra E Fischer; Julie M Wilson; Richard Moffitt; Jennifer Knox; Alexander Krasnitz; Steven Gallinger; David A Tuveson Journal: Cancer Discov Date: 2018-05-31 Impact factor: 38.272
Authors: Nicholas Willumsen; Cecilie L Bager; Diana J Leeming; Victoria Smith; Morten A Karsdal; David Dornan; Anne-Christine Bay-Jensen Journal: BMC Cancer Date: 2013-11-21 Impact factor: 4.430